Search 

Evestia Clinical is a global, mid‑size CRO dedicated to supporting life science innovators from Phase I to IV through a single‑partner model.  They provide a flexible, tailored suite of clinical trial services, from single service or FSP to full‑service, with primary focus in oncology, neurology, and rare diseases, and additional expertise in immunology and inflammation.

Anchored by a core presence in the US, UK, Europe, and Australia, Evestia Clinical delivers fast start‑up, pragmatic execution, and integrated study services, helping bring life‑changing therapies to patients sooner.

Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines.

GreyRigge Associates is a global biotech partner delivering consultancy, management expertise and training across the entire product development journey. Our extensive biopharmaceutical industry experience and pragmatic, agile approach enables transformational success by accelerating our clients’ medicines to market.

Our new tagline “Chemistry that delivers” captures the core of our offer: deep expertise in synthetic chemistry and scale-up, applied with rigour and purpose to deliver reliable outcomes. It speaks to our chemistry-first approach and our ability to support science-led organisations across pharmaceuticals, diagnostics, and advanced materials, not just in theory, but in practice.
Just as importantly, HFR remains a highly collaborative partner. Our director-led model and long-standing relationships mean you work directly with experienced chemists who understand your challenges and are invested in your success. That hands-on partnership continues to be central to how we operate.

HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability. 

Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.